Praxis Precision Medicines, Inc. Board of Directors

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Mr. Alex Nemiroff J.D.

Mr. Alex Nemiroff J.D.

General Counsel & Secretary

Dr. Karl Hansen Ph.D.

Dr. Karl Hansen Ph.D.

Chief Technical Operations Officer

Ms. Megan T. Sniecinski

Ms. Megan T. Sniecinski

Chief Business Officer

Ms. Kelly McCue

Ms. Kelly McCue

Chief People Officer

Lauren Mastrocola

Lauren Mastrocola

VP of Finance & Principal Accounting Officer

Mr. Alex Kane

Mr. Alex Kane

VP of Investor Relations & Corporate Communications

Ms. Alyssa J. S. Wyant

Ms. Alyssa J. S. Wyant

Chief Regulatory & Quality Officer

Dr. Steven Petrou B.Sc. (Hons.), Ph.D.

Dr. Steven Petrou B.Sc. (Hons.), Ph.D.

Co-Founder & Chief Scientific Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.